Journal ArticleDOI
Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience.
Ian C. Lawrance,Graham L. Radford-Smith,Graham L. Radford-Smith,Peter A. Bampton,Jane M. Andrews,Pok-Kern Tan,Anthony Croft,Richard B. Gearry,Timothy H. Florin +8 more
Reads0
Chats0
TLDR
The aim of this study was to examine the Australian/New Zealand experience of serious infections and TB in IBD patients receiving anti‐TNF‐α therapy from 1999–2009.Abstract:
Ian C Lawrance, Graham L Radford-Smith, Peter A Bampton, Jane M Andrews, Pok-Kern Tan, Anthony Croft, Richard B Gearry and Timothy H J Florinread more
Citations
More filters
Journal ArticleDOI
Cytomegalovirus pneumonia in patients with inflammatory bowel disease: a systematic review
TL;DR: CMV pneumonia should always be suspected in IBD patients who present with fever and tachypnea, especially if the latter is worsening and/or is associated with dyspnea, and treatment must be early and specific.
Journal ArticleDOI
Invasive fungal infections in pediatric patients treated with tumor necrosis alpha (TNF-α) inhibitors
TL;DR: Critically analyzed literature on invasive fungal infections occurring in association with TNFα inhibitors alone or in combination with other immunosuppressive agents, with a focus on pediatric patients, to provide a framework of evaluating the risk for IFIs in this population.
Journal ArticleDOI
Adalimumab: Another Medication Related to Osteonecrosis of the Jaws?
Andrea Cassoni,Umberto Romeo,Valentina Terenzi,Marco Della Monaca,Oriana Rajabtork Zadeh,Ingrid Raponi,Maria Teresa Fadda,Antonella Polimeni,Valentino Valentini +8 more
TL;DR: The authors suggest that the biologic therapy with an anti-TNF-α antibody might promote the manifestation of osteonecrosis and compromise oral healing capacity of the bone.
Journal ArticleDOI
Efficacy and safety of interferon-gamma-targeted therapy in Crohn's disease: a systematic review and meta-analysis of randomized controlled trials.
TL;DR: Anti-interferon-gamma therapy is safe and effective for treating active Crohn's disease despite slow onset of action.
Journal ArticleDOI
Osteonecrosis of the jaw in a Crohn’s disease patient following a course of Bisphosphonate and Adalimumab therapy: a case report
Raimund H.M. Preidl,Tobias Ebker,Martin Raithel,Falk Wehrhan,Friedrich Wilhelm Neukam,Philipp Stockmann +5 more
TL;DR: This patient with a medical history of Crohn’s disease and gastrointestinal remission under Adalimumab therapy presented with osteonecrosis of the jaw after suspended oral and intravenous Bisphosphonate therapy implicating that the biologic therapy with an anti-TNF-α antibody might promote the manifestation of oste onecrosis and compromise oral healing capacity.
References
More filters
Journal ArticleDOI
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Stephen B. Hanauer,Brian G. Feagan,Gary R. Lichtenstein,Lloyd Mayer,Stefan Schreiber,Jean-Frederic Colombel,Daniel Rachmilewitz,Douglas C. Wolf,Allan Olson,Weihang Bao,Paul Rutgeerts +10 more
TL;DR: Patients with Crohn's disease who respond to an initial dose of infliximab are more likely to be in remission at weeks 30 and 54, to discontinue corticosteroids, and to maintain their response for a longer period of time, if inflIXimab treatment is maintained every 8 weeks.
Journal ArticleDOI
Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent
Joseph Keane,Sharon K. Gershon,Robert P. Wise,Elizabeth Mirabile-Levens,John Kasznica,William D. Schwieterman,Jeffrey Siegel,M. Miles Braun +7 more
TL;DR: Infliximab is a humanized antibody against tumor necrosis factor α (TNF-α) that is used in the treatment of Crohn's disease and rheumatoid arthritis but there is no direct evidence of a protective role of TNF- α in patients with tuberculosis.
Journal ArticleDOI
Infliximab for induction and maintenance therapy for ulcerative colitis.
Paul Rutgeerts,William J. Sandborn,Brian G. Feagan,Walter Reinisch,Allan Olson,Jewel Johanns,Suzanne Travers,Daniel Rachmilewitz,Stephen B. Hanauer,Gary R. Lichtenstein,Willem J.S. de Villiers,Daniel H. Present,Bruce E. Sands,Jean-Frederic Colombel +13 more
TL;DR: Patients with moderate-to-severe active ulcerative colitis treated with infliximab at weeks 0, 2, and 6 and every eight weeks thereafter were more likely to have a clinical response at weeks 8, 30, and 54 than were those receiving placebo.
Journal ArticleDOI
Toward an Integrated Clinical, Molecular and Serological Classification of Inflammatory Bowel Disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology
Mark S. Silverberg,Jack Satsangi,Tariq Ahmad,Ian D. Arnott,Charles N. Bernstein,Steven R. Brant,Renzo Caprilli,Jean-Frederic Colombel,Christoph Gasche,Karel Geboes,Derek P. Jewell,Amir Karban,Edward V. Loftus,A. Salvador Peña,Robert H. Riddell,David B. Sachar,Stefan Schreiber,A. Hillary Steinhart,Stephan R. Targan,Severine Vermeire,Bryan F. Warren +20 more
TL;DR: The introduction of a widely acceptable clinical subclassification is strongly advocated, which would allow detailed correlations among serotype, genotype and clinical phenotype to be examined and confirmed in independent cohorts of patients and, thereby, provide a vital foundation for future work.
Journal ArticleDOI
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
Jean-Frederic Colombel,William J. Sandborn,Paul Rutgeerts,Robert Enns,Stephen B. Hanauer,Remo Panaccione,Stefan Schreiber,Dan Byczkowski,Ju Li,J. D. Kent,Paul F. Pollack +10 more
TL;DR: Adalimumab was well-tolerated, with a safety profile consistent with previous experience with the drug, and was significantly more effective than placebo in maintaining remission in moderate to severe CD through 56 weeks.
Related Papers (5)
European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease.
Jean-François Rahier,Fernando Magro,Candida Abreu,Alessandro Armuzzi,Shomron Ben-Horin,Yehuda Chowers,Mario Cottone,L. de Ridder,Glen A. Doherty,Robert Ehehalt,Maria Esteve,K.H. Katsanos,Charlie W. Lees,Eithne MacMahon,Tom G. Moreels,Walter Reinisch,Herbert Tilg,Lydjie Tremblay,Gigi Veereman-Wauters,N. Viget,Yazdan Yazdanpanah,Rami Eliakim,Jean-Frederic Colombel +22 more